
|Videos|February 15, 2021
Relapsed/Refractory HER2+ Metastatic Breast Cancer
Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.
Advertisement
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Giredestrant Displays IDFS Improvement vs SOC ET in ER+/HER2– BC
2
Sacituzumab Govitecan Does Not Meet Statistical Significance in HR+/HER2– mBC
3
Pembrolizumab/Radiation Improves T Cell Infiltration in Early Breast Cancer
4
QOL Improvements Noted After CAR T-Cell Therapy in LBCL
5














































































